Drugs / GSK163090
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00559299 | Nov 2007 → Jun 2008 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00536679 | Sep → Nov 2007 | mixed anxiety and depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00435695 Comparator | Nov 2006 → Dec 2007 | mixed anxiety and depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00896363 Comparator | Apr 2009 → Feb 2010 | depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK163090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00435695 ↗ |
| Action | Inhibit | “Serotonin 1a (5-HT1a) receptor antagonist” CHEMBL1631540 ↗3“Serotonin 1d (5-HT1d) receptor antagonist” CHEMBL1631540 ↗ “Serotonin 1b (5-HT1b) receptor antagonist” CHEMBL1631540 ↗ “Serotonin transporter antagonist” CHEMBL1631540 ↗ |
| Modality | Small molecule | — CHEMBL1631540 ↗ |
| Route | Oral | “Single Oral Doses of GSK163090” NCT00435695 ↗ |
| Target | HTR1A | “Serotonin 1a (5-HT1a) receptor antagonist” CHEMBL1631540 ↗ |
| Target | HTR1B | “Serotonin 1b (5-HT1b) receptor antagonist” CHEMBL1631540 ↗ |
| Target | HTR1D | “Serotonin 1d (5-HT1d) receptor antagonist” CHEMBL1631540 ↗ |
| Target | SLC6A4 | “Serotonin transporter antagonist” CHEMBL1631540 ↗ |